Related Experiment Video
Updated: May 1, 2026
10:11
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
22.4K
Septin 7 immunoexpression in papillary thyroid carcinoma: a preliminary study
Yusuf Ziya Igci1, Suna Erkilic2, Ahmet Arslan1
1University of Gaziantep, Faculty of Medicine, Department of Medical Biology, Gaziantep, Turkey.
Pathology, Research and Practice
|April 2, 2014
Summary
SEPT7 protein expression is significantly lower in encapsulated follicular variant papillary thyroid carcinoma (FVPTC(e)) compared to benign nodules. This finding suggests a distinct molecular profile for FVPTC(e) in thyroid cancer diagnosis.
Area of Science:
- Oncology
- Molecular Pathology
- Biochemistry
Background:
- Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy.
- Distinguishing follicular variant PTC (FVPTC) from classical PTC (CVPTC) can be diagnostically challenging due to similar nuclear features.
- Molecular markers may aid in PTC diagnosis.
Purpose of the Study:
- To investigate the expression levels of SEPT7 protein in different subtypes of papillary thyroid carcinoma.
- To compare SEPT7 protein expression between encapsulated FVPTC (FVPTC(e)), classical PTC (CVPTC), and benign hyperfunctioning thyroid nodules (HypN).
Main Methods:
- Immunohistochemistry was utilized to assess nuclear, cytoplasmic, and overall SEPT7 protein expression.
- Tissue samples included FVPTC(e) (n=25), CVPTC (n=15), and HypN (n=15).
Main Results:
- SEPT7 expression (nuclear, cytoplasmic, overall) was significantly lower in FVPTC(e) compared to HypN (p=0.02, p=0.001, p=0.002).
- Nuclear SEPT7 expression was significantly lower in CVPTC versus HypN (p=0.004), with no significant difference in cytoplasmic or overall expression.
- Benign hyperfunctioning nodules (HypN) exhibited the highest SEPT7 expression levels.
Conclusions:
- Reduced SEPT7 protein expression in FVPTC(e) suggests a unique molecular signature.
- SEPT7 may serve as a potential biomarker for differentiating FVPTC(e) from other thyroid lesions.
